Abstract:Cardiac arrhythmias cause significant morbidity and mortality and pose a major public health problem. They arise from disruptions in the normally orderly propagation of cardiac electrophysiological activation and recovery through successive cardiomyocytes in the heart. They reflect abnormalities in automaticity, initiation, conduction, or recovery in cardiomyocyte excitation. The latter properties are dependent on surface membrane electrophysiological mechanisms underlying the cardiac action potential. Their disruption results from spatial or temporal instabilities and heterogeneities in the generation and propagation of cellular excitation. These arise from abnormal function in their underlying surface membrane, ion channels, and transporters, as well as the interactions between them. The latter, in turn, form common regulatory targets for the hierarchical network of diverse signaling mechanisms reviewed here. In addition to direct molecular-level pharmacological or physiological actions on these surface membrane biomolecules, accessory, adhesion, signal transduction, and cytoskeletal anchoring proteins modify both their properties and localization. At the cellular level of excitation–contraction coupling processes, Ca 2+ homeostatic and phosphorylation processes affect channel activity and membrane excitability directly or through intermediate signaling. Systems -level autonomic cellular signaling exerts both acute channel and longer-term actions on channel expression. Further upstream intermediaries from metabolic changes modulate the channels both themselves and through modifying Ca 2+ homeostasis. Finally, longer-term organ -level inflammatory and structural changes, such as fibrotic and hypertrophic remodeling, similarly can influence all these physiological processes with potential pro-arrhythmic consequences. These normal physiological processes may target either individual or groups of ionic channel species and alter with particular pathological conditions. They are also potentially alterable by direct pharmacological action, or effects on longer-term targets modifying protein or cofactor structure, expression, or localization. Their participating specific biomolecules, often clarified in experimental genetically modified models, thus constitute potential therapeutic targets. The insights clarified by the physiological and pharmacological framework outlined here provide a basis for a recent modernized drug classification. Together, they offer a translational framework for current drug understanding. This would facilitate future mechanistically directed therapeutic advances, for which a number of examples are considered here. The latter are potentially useful for treating cardiac, in particular arrhythmic, disease.

Fibroblast Growth Factor Homologous Factors Are Potential Ion Channel Modifiers Associated with Cardiac Arrhythmias

Fibroblast Proliferation Alters Cardiac Excitation Conduction and Contraction: a Computational Study.

Excitation-Contraction Coupling Between Human Atrial Myocytes with Fibroblasts and Stretch Activated Channel Current: A Simulation Study.

Research progress of fibroblast growth factor homologous factor 1 in the pathogenesis of arrhythmia

Simulation of Atrial Fibrosis Using Coupled Myocyte-Fibroblast Cellular and Human Atrial Models.

Theoretical Investigation Of The Mechanism Of Heart Failure Using A Canine Ventricular Cell Model: Especially The Role Of Up-Regulated Camkii And Sr Ca2+ Leak

Progress on role of ion channels of cardiac fibroblasts in fibrosis

Unlocking the secrets of Cardiac development and function: the critical role of FHL2

Fibroblast Growth Factor 1 Reduces Pulmonary Vein and Atrium Arrhythmogenesis via Modification of Oxidative Stress and Sodium/Calcium Homeostasis

Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis

Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation

Role of ion channels in heart failure and channelopathies

Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions

High Molecular Weight Fibroblast Growth Factor-2 in the Human Heart Is a Potential Target for Prevention of Cardiac Remodeling

Unveiling the Role of Ion Currents in Action Potential Modulation

Fibroblast Growth Factor 21 Protects Against Atrial Remodeling Via Reducing Oxidative Stress.

Fibroblast Growth Factor 21 Ameliorates NaV1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes

Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness

Abnormal phosphorylation / dephosphorylation and Ca2+ dysfunction in heart failure

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

Remodeling of Ion Channel Trafficking and Cardiac Arrhythmias